Calcium Gluconate Activated in Anterior Disc Displacement With Reduction of the Temporomandibular Joint
Calcium Gluconate Activated Versus Non-Activated Platelet Rich Plasma in Anterior Disc Displacement With Reduction of the Temporomandibular Joint: Randomized Clinical Trial.
To compare the efficacy of retro discal injection of calcium gluconate-activated PRP versus non-activated PRP in adults with Anterior Disc Displacement with Reduction (ADDWR). Efficacy will be measured by the reduction of symptoms and the restoration of function, specifically targeting the normal Maximum Mouth Opening (MMO) range
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
To compare the efficacy of retro discal injection of calcium gluconate-activated PRP versus non-activated PRP in adults with Anterior Disc Displacement With Reduction (ADDWR). Efficacy will be measured by the reduction of symptoms and the restoration of function, specifically targeting the normal Maximum Mouth Opening (MMO) range.
Although laboratory evidence indicates that activation with Calcium Gluconate significantly enhances growth factor release compared to non-activated (resting) PRP, it remains clinically unproven whether this biochemical advantage translates into superior symptomatic relief and functional disc repositioning in TMJ patients. This trial seeks to determine if the additional step of activation yields a statistically significant clinical benefit over the simpler, non-activated technique.
By combining the biologically optimized injectate (Calcium Gluconate-Activated PRP) with the anatomically specific retrodiscal injection site-which is critical for addressing disc instability-this study aims to define a superior, evidence-based protocol. Determining the efficacy of this specific combination is essential for establishing a "gold standard" for non-surgical ADDWR management.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mohamed A. Osama, BDS
- Phone Number: 01013127607
- Email: mohamed.madkour@dentistry.cu.edu.eg
Study Locations
-
-
-
Cairo, Egypt
- Recruiting
- Cairo University
-
Contact:
- Mohamed A. Osama, BDS
- Phone Number: 01013127607
- Email: mohamed.madkour@dentistry.cu.edu.eg
-
Contact:
- Nada Abd El Sattar Mohamed Kotb
- Phone Number: 01281679119
- Email: nada_abdelsattar@dentistry.cu.edu.eg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18-65 years.
- Clinical and MRI diagnosis of ADDWR per DCTMD criteria.
- Baseline VAS pain score 4-10.
- Failure of at least 2 conservative treatments (splint therapy, physiotherapy, NSAIDs) for 3 months.
- Written informed consent.
Exclusion Criteria:
-
• Systemic inflammatory arthritis (Rheumatoid arthritis, etc.).
- Recent TMJ surgery or intra-articular injection within the last 6 months.
- Pregnancy or lactation.
- Active TMJ infection or malignancy.
- Coagulopathy or anticoagulant therapy.
- Contraindications to MRI (e.g., pacemaker).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: activated platelet-rich plasma
Intra-articular retro discal injection of autologous platelet-rich plasma (PRP) |
Intra-articular retrodiscal injection of autologous platelet-rich plasma (PRP) activated with 0.5 milliliters of 10% sterile calcium gluconate per 5 milliliters of prepared PRP, administered as a single anatomical landmark-guided injection into the retrodiscal tissue. |
|
Active Comparator: non-activated platelet-rich plasma
Intra-articular retrodiscal injection of autologous non-activated platelet-rich plasma |
Intra-articular retrodiscal injection of autologous non-activated platelet-rich plasma, prepared using identical double-centrifugation technique and administered using identical injection protocol and volume |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximal Interincisal Opening (MIO)
Time Frame: 3 months
|
measuring in millimeters using ruler |
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Intensity
Time Frame: 3 months
|
Visual Analog Scale (0-10) |
3 months
|
|
Return of disc to normal position
Time Frame: 3 months
|
using MRI imaging |
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- omfs-6-2026
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.